Comparative Pharmacology
Head-to-head clinical analysis: MIDODRINE HYDROCHLORIDE versus PROAMATINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDODRINE HYDROCHLORIDE versus PROAMATINE.
MIDODRINE HYDROCHLORIDE vs PROAMATINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midodrine is a prodrug that is metabolized to desglymidodrine, an alpha1-adrenergic receptor agonist. Desglymidodrine increases peripheral arterial and venous tone, leading to increased blood pressure through vasoconstriction.
Midodrine is a prodrug that is converted to desglymidodrine, an alpha1-adrenergic receptor agonist. It causes vasoconstriction and increases peripheral vascular resistance, leading to an increase in blood pressure.
5-10 mg orally every 8 hours during daytime hours (last dose before evening meal to prevent supine hypertension).
10 mg orally three times daily, with doses given in the morning, at midday, and in the late afternoon to avoid nighttime supine hypertension.
None Documented
None Documented
Midodrine: ~0.5 hours; desglymidodrine: ~2-4 hours (terminal half-life). Clinical context: dosing every 3-4 hours to maintain effect.
Terminal elimination half-life is approximately 0.4 hours (range 0.2-0.7 hours). Clinically, due to rapid elimination, repeated dosing every 3-4 hours is required to maintain therapeutic effect.
Renal excretion: approximately 80% as unchanged drug and active metabolite (desglymidodrine). Biliary/fecal: minor (<10%).
Primarily renal excretion of unchanged drug; approximately 40-80% of an administered dose is excreted unchanged in urine. Minor biliary/fecal excretion accounts for less than 5%.
Category A/B
Category C
Alpha-1 Agonist
Alpha-1 Agonist